Article Text

Download PDFPDF
Journal club summaries
What’s hot that the other lot got
  1. Kavina Shah
  1. Correspondence to Dr Kavina Shah, Rheumatology ST4, Hammersmith Hospital, London W12 0HS, UK; kavina.shah{at}nhs.net

Statistics from Altmetric.com

Cyclophosphamide for connective tissue disease-associated interstitial lung disease (CTD-ILD)

Cyclophosphamide is the accepted standard of care for individuals with progressive CTD-ILD. Its efficacy and adverse effects in CTD-ILD has recently been published in a Cochrane review (Barnes et al. Cochrane Database Syst Rev 2018;1:CD010908). Four trials with 495 participants (mostly with systemic sclerosis) were included. When compared with placebo, there was a statistically significant but clinically small improvement in post cyclophosphamide FVC (% mean difference (MD) 2.83, 95% CI 0.80 to 4.87; p=0.006) but no difference in post cyclophosphamide DLCO (% MD −1.68, 95% CI −4.37 to 1.02; p=0.22; two trials, 182 participants). When comparing cyclophosphamide with mycophenolate mofetil (MMF) at 1 year (two trials, 149 participants), there was no significant difference in lung function (p=0.61) or diffusion capacity (p=0.76). Improvement in lung function was more pronounced in patients with worse baseline spirometry and fibrosis scores. As may be expected, there was a greater risk of side effects with cyclophosphamide when compared with both placebo and …

View Full Text

Footnotes

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.